About Us
The Future of Biofilm Control Is Enzymatic
Biofilms are a hidden driver of chronic inflammation, infection, and treatment resistance across a wide range of conditions. At Inoculus Ventures, we are building a platform of targeted enzyme-based solutions that break down biofilm structure and adhesion without relying on antibiotics or harsh chemicals.
​
Our early focus was on the ocular surface, where biofilm-related inflammation contributes to diseases like blepharitis and dry eye. From that foundation, we are expanding into broader areas where biofilm disruption can make a meaningful impact.
We believe enzymes offer a more precise and sustainable approach by removing the biofilm rather than just masking its effects.
Why Biofilms Matter
Biofilms are protective bacterial communities that form on surfaces in the body and environment. They interfere with immune clearance and reduce the effectiveness of antibiotics and standard treatments. More than 80 percent of chronic infections involve biofilms, yet most consumer and clinical products still overlook them.
Our enzyme-based solutions are designed to break apart the biofilm matrix and loosen bacterial attachment. This allows for more effective removal and helps support natural healing processes.